The U.S. Senate added a new iteration of the Biosecure Act as an amendment to the National Defense Authorization Act, advancing language aimed at restricting federal funding or contracts with certain foreign biotechnology firms of concern. The move, proposed by Sen. Bill Hagerty, shifts the bill into a vehicle with strong odds of passage. The Senate version removes explicit company names that torpedoed prior versions but maintains a mechanism to limit government ties with firms deemed security risks; the House passed a different defense bill without Biosecure. The two chambers must reconcile their bills before final enactment. Industry groups warned the legislation could complicate collaborations, supply chains and research partnerships; companies and academic centers will monitor reconciliation and potential implementation timelines closely.